Literature DB >> 2683994

New prognostic indicators in resectable breast cancer (review).

G S Jotti1.   

Abstract

Despite advances in early diagnosis and primary treatment of breast cancer with surgery, radiation therapy or both modalities, more than one-third of newly diagnosed patients will develop recurrent or systemic disease and ultimately die. In recent years, systemic adjuvant treatment has shown positive results in high-risk women and tumor mortality has significantly decreased in patients entered clinical trials. This review outlines old and new prognostic indicators which will enable clinicians to improve the selection of patients who are real candidates to adjuvant chemotherapy and/or hormonal therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2683994

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma.

Authors:  H Schimmelpenning; E T Eriksson; U G Falkmer; E Azavedo; G Svane; G U Auer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

2.  Cytosol protein content and prognosis in operable breast cancer. Correlations with steroid hormone receptors and other prognostic factors.

Authors:  J A Søreide; O A Lea; S Kvinnsland
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.